Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BPT567 |
| Synonyms | |
| Therapy Description |
BPT567 is composed of an anti-CD274 (PD-1) antibody conjugated to an engineered IL-18 variant, which potentially enhances antitumor immune response (Cancer Res (2024) 84 (6_Supplement): 4071). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BPT567 | BPT-567|BPT 567 | PD-L1/PD-1 antibody 133 | BPT567 is composed of an anti-CD274 (PD-1) antibody conjugated to an engineered IL-18 variant, which potentially enhances antitumor immune response (Cancer Res (2024) 84 (6_Supplement): 4071). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06779851 | Phase I | BPT567 | A Study to Evaluate Safety and Tolerability of BPT567 in Patients With Advanced Solid Tumors (SUMMIT-1) | Recruiting | USA | 0 |